The multiple frame trigger adjusts the acquisition of a series of consecutive frames, usually with ECG triggering. Multiple frame triggers are used in harmonic power Doppler modes to identify motion artifacts in contrast enhanced Doppler imaging.

Contrast agents improve the sensitivity of vascular Doppler ultrasound, for example in cerebrovascular sonography or examinations of deep abdominal vessels. They also enlarge the role of transcranial Doppler. Microbubbles can be used with various modes e.g., color and power Doppler imaging, as well as pulsed-wave Doppler to increase the signal intensity. However, the ultrasound system must be suitable for contrast enhanced technology.
Microbubbles usually stay within the vascular space; nevertheless, the contrast enhancement is limited to 2−6 minutes caused by physiologic clearance and bubble destruction.
Depended on the application, contrast agents can be administered with a different injection rate e.g., bolus injection, slow injection, or continuous infusion. Stable, homogeneous, and prolonged enhancement can be obtained with perfusion, lasting until the infusion is stopped.

See also Cerebrovascular Ultrasonography, Multiple Frame Trigger.

(HPD) Harmonic power Doppler is currently one of the most sensitive techniques for detecting ultrasound contrast agents. HPD works by transmitting multiple pulses toward the object to be imaged and detecting the pulse-to-pulse changes in the received echo signals.
Second harmonic bandbass filtering is applied to the received signals to exploit the non-linear behavior of scattering from bubbles (clutter). Harmonic power Doppler operates best at high output levels because of increased contrast destruction, and pulse amplitudes close to the maximum allowed are used much of the time.
With a high mechanical index, non-linear propagation of the sound will cause significant harmonic components from tissue, and the contrast agent to tissue ratio will decrease.
Also called Harmonic Power Angio. See also Multiple Frame Trigger.

[This entry is marked for removal.]

'POINT Biomedical was a privately held pharmaceutical company, founded in 1996 to pursue technologies related to imaging and drug delivery. POINT's core technology was based upon an ultrasonically responsive two-layer, biodegradable microsphere or BiSphere™. One of the most important features of this technology is the ability to noninvasively trigger the BiSpheres™ to release their contents at sites within the body using externally generated pulses of ultrasound. From this basic platform, POINT was developing a pipeline of products that leverage the unique properties of the BiSphere™ technology in the areas of imaging and therapeutics. POINT has initially focused development of this platform on the assessment of tissue specific blood flow. The lead product, CARDIOsphere®, is a pharmaceutical agent that will enable cardiologists to perform myocardial perfusion imaging studies in the office setting using ultrasound rather than more expensive and cumbersome nuclear medicine (or radioisotope) techniques.'
'According to BioSpace, Tom Feldman, ex-CEO of Point BioMedical, the company's lead investor, Vendanta Capital has chosen not to follow through with the second half of its $50 million private equity financing. Point BioMedical has withdrawn the new drug application for its molecular imaging agent CARDIOsphere and is liquidating its assets to avoid a formal bankruptcy proceeding in 2008.'